Form 4: Coherus Oncology Director Granted 112,000 Stock Options

Coherus Oncology, Inc. Director Charles W. Newton was granted 112,000 stock options with an exercise price of $0.7904, vesting fully on June 11, 2026.

Summary

• Charles W. Newton, a Director of Coherus Oncology, Inc. (CHRS), was granted 112,000 stock options.
• The stock options have an exercise price of $0.7904 per share.
• The options are scheduled to vest 100% on the one-year anniversary of June 11, 2025, which is June 11, 2026, contingent upon Mr. Newton's continued service relationship with the Issuer.
• The expiration date for these stock options is June 12, 2035.
• Following this reported transaction, Mr. Newton beneficially owns 112,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed as a positive event as it aligns the director's interests with shareholder value. It is a routine compensation event rather than a major strategic announcement, leading to a moderately positive sentiment score.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance and value creation.
• The exercise price of $0.7904 is relatively low, offering significant potential upside for the director if Coherus Oncology's stock price appreciates.

Risks

• The ultimate value of the granted stock options is directly tied to the future market performance of Coherus Oncology's common stock; if the stock price does not rise above the exercise price, the options may expire worthless.
• The vesting of the options is conditional on Charles W. Newton's continued service with the Issuer until the vesting date (June 11, 2026), meaning the options could be forfeited if his service relationship terminates prematurely.

Future Outlook

This SEC Form 4 filing exclusively reports an insider equity grant and does not contain any forward-looking statements or guidance regarding Coherus Oncology's future financial performance, strategic initiatives, or operational outlook. It primarily indicates future potential equity ownership for a director.

Industry Context

The grant of stock options to directors is a standard and widely adopted practice within the biotechnology and pharmaceutical industries, including companies focused on oncology like Coherus Oncology. This form of compensation is designed to align the interests of board members with the long-term success and shareholder value creation of the company. This specific grant to Director Charles W. Newton is consistent with routine equity compensation practices for board members.

Comparison to Industry Standards

• The practice of granting stock options to directors is a common and accepted form of compensation across publicly traded companies, particularly prevalent in the biotech sector.
• While the specific number of options (112,000) and the exercise price ($0.7904) would typically be benchmarked against Coherus Oncology's peer group compensation data and the director's specific role and tenure, this document alone does not provide sufficient information for a direct quantitative comparison to specific comparable companies (e.g., Amgen, Gilead Sciences, Bristol Myers Squibb) or their director compensation packages.
• However, the structure of the grant, including its vesting schedule and fixed exercise price, aligns with general industry norms for equity-based incentive compensation.

Stakeholder Impact

• Shareholders: Potential positive impact due to enhanced alignment of the director's interests with stock performance. There is no immediate dilution from the grant itself, but potential future dilution upon exercise of the options.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Charles W. Newton's continued service with Coherus Oncology, Inc. is required until at least June 11, 2026, for the granted stock options to fully vest.
• Following vesting, Charles W. Newton has the potential to exercise the stock options between June 11, 2026, and June 12, 2035, assuming the company's stock price is above the exercise price.

Key Dates

Recommendation

Keywords

Coherus Oncology, CHRS, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Executive Compensation